Masaki Ishigai

1.1k total citations
52 papers, 748 citations indexed

About

Masaki Ishigai is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Masaki Ishigai has authored 52 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 19 papers in Oncology and 12 papers in Pharmacology. Recurrent topics in Masaki Ishigai's work include Drug Transport and Resistance Mechanisms (14 papers), Pharmacogenetics and Drug Metabolism (11 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Masaki Ishigai is often cited by papers focused on Drug Transport and Resistance Mechanisms (14 papers), Pharmacogenetics and Drug Metabolism (11 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). Masaki Ishigai collaborates with scholars based in United States, Japan and Switzerland. Masaki Ishigai's co-authors include Yoshinori Aso, Naoaki Murao, Motohiro Kato, Hideyuki Yasuno, Yasushi Shimonaka, Tsuyoshi Shimoboji, Takashi Nakai, Kazunari Akiyoshi, Kenji Kumaki and Kiyoshi Tatsumi and has published in prestigious journals such as SHILAP Revista de lepidopterología, Analytical Biochemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Masaki Ishigai

51 papers receiving 705 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Masaki Ishigai United States	16	254	128	122	107	90	52	748
Changzheng Li China	22	719 2.8×	240 1.9×	47 0.4×	66 0.6×	64 0.7×	78	1.4k
Yang Sai China	17	427 1.7×	280 2.2×	297 2.4×	40 0.4×	31 0.3×	44	1.0k
Philip Kestell New Zealand	20	571 2.2×	348 2.7×	218 1.8×	92 0.9×	42 0.5×	52	1.0k
Cindy Q. Xia United States	20	481 1.9×	777 6.1×	281 2.3×	120 1.1×	50 0.6×	47	1.4k
Yonghua Ling United States	13	307 1.2×	115 0.9×	31 0.3×	112 1.0×	20 0.2×	20	604
Joanne Brodfuehrer United States	14	347 1.4×	370 2.9×	113 0.9×	16 0.1×	27 0.3×	36	934
José A. Guerrero Spain	15	262 1.0×	151 1.2×	34 0.3×	362 3.4×	11 0.1×	38	1.0k
Joe Palandra United States	15	282 1.1×	360 2.8×	136 1.1×	13 0.1×	36 0.4×	25	838
Tonika Bohnert United States	9	228 0.9×	138 1.1×	61 0.5×	23 0.2×	39 0.4×	9	558
Guoqing Gong China	16	305 1.2×	76 0.6×	57 0.5×	57 0.5×	22 0.2×	42	799

Countries citing papers authored by Masaki Ishigai

Since Specialization

Citations

This map shows the geographic impact of Masaki Ishigai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masaki Ishigai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masaki Ishigai more than expected).

Fields of papers citing papers by Masaki Ishigai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masaki Ishigai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masaki Ishigai. The network helps show where Masaki Ishigai may publish in the future.

Co-authorship network of co-authors of Masaki Ishigai

This figure shows the co-authorship network connecting the top 25 collaborators of Masaki Ishigai. A scholar is included among the top collaborators of Masaki Ishigai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masaki Ishigai. Masaki Ishigai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ishigai, Masaki, et al.. (2018). Characterization of phase I and phase II metabolism of UR-1102, a novel agent for the treatment of gout. Drug Metabolism and Pharmacokinetics. 33(1). S29–S29. 1 indexed citations

Takahashi, Ayako, Shunsuke Ito, Mariko Yano, et al.. (2018). MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity. mAbs. 10(8). 1168–1181. 29 indexed citations

Nagao, Shunsuke, Kenji Takanashi, Motohiro Kato, et al.. (2016). Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib. Xenobiotica. 47(12). 1042–1051. 10 indexed citations

Kato, Motohiro, et al.. (2015). Evaluation of the appropriate time range for estimating the apparent permeability coefficient (Papp) in a transcellular transport study. International Journal of Pharmaceutics. 495(2). 963–971. 19 indexed citations

Haraya, Kenta, Tatsuhiko Tachibana, Masahiko Nanami, & Masaki Ishigai. (2014). Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica. 44(12). 1127–1134. 22 indexed citations

Yamaguchi, Koji, Shunsuke Nagao, Mika Sato, et al.. (2014). In vitroprofiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica. 45(3). 230–238. 21 indexed citations

Mitsui, T, Takayuki Nemoto, Shunsuke Nagao, et al.. (2014). A Useful Model Capable of Predicting the Clearance of Cytochrome P450 3A4 (CYP3A4) Substrates in Humans: Validity of CYP3A4 Transgenic Mice Lacking Their Own Cyp3a Enzymes. Drug Metabolism and Disposition. 42(9). 1540–1547. 10 indexed citations

Saitoh, Ryoichi, et al.. (2013). Assessing the Impact of HER2 Status on the Antitumor Activity of an HSP90 Inhibitor in Human Tumor Xenograft Mice Using Pharmacokinetic–Pharmacodynamic Modeling. Drug Metabolism and Pharmacokinetics. 29(2). 185–191.

Yamaguchi, Koji, Motohiro Kato, Masayuki Suzuki, et al.. (2013). In Vitro–In Vivo Correlation of the Inhibition Potency of Sodium-Glucose Cotransporter Inhibitors in Rat: A Pharmacokinetic and Pharmacodynamic Modeling Approach. Journal of Pharmacology and Experimental Therapeutics. 345(1). 52–61. 19 indexed citations

10.

Nakata, Katsunori, Ryoichi Saitoh, Jun Amano, et al.. (2012). Alteration of intracellular secretory acute phase response proteins expressed in human hepatocyte induced by exposure with interleukin-6. Cytokine. 59(2). 317–323. 14 indexed citations

11.

Ogawa, Kotaro, et al.. (2012). A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data. Xenobiotica. 43(5). 468–478. 11 indexed citations

12.

Nakai, Takashi, et al.. (2012). Injectable Hydrogel for Sustained Protein Release by Salt‐Induced Association of Hyaluronic Acid Nanogel. Macromolecular Bioscience. 12(4). 475–483. 83 indexed citations

13.

Kashiwagi, Hirotaka, Yoshiyuki Ono, Kazuki Shimizu, et al.. (2011). Novel nonsecosteroidal vitamin D3 carboxylic acid analogs for osteoporosis, and SAR analysis. Bioorganic & Medicinal Chemistry. 19(16). 4721–4729. 14 indexed citations

14.

Kato, Motohiro, et al.. (2011). Bridging from Preclinical to Clinical Studies for Tyrosine Kinase Inhibitors Based on Pharmacokinetics/Pharmacodynamics and Toxicokinetics/Toxicodynamics. Drug Metabolism and Pharmacokinetics. 26(6). 612–620. 22 indexed citations

15.

Yamaguchi, Koji, Motohiro Kato, Masayuki Suzuki, et al.. (2011). Pharmacokinetic and Pharmacodynamic Modeling of the Effect of an Sodium-Glucose Cotransporter Inhibitor, Phlorizin, on Renal Glucose Transport in Rats. Drug Metabolism and Disposition. 39(10). 1801–1807. 19 indexed citations

16.

Murao, Naoaki, Masaki Ishigai, Hideyuki Yasuno, Yasushi Shimonaka, & Yoshinori Aso. (2007). Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean‐up. Rapid Communications in Mass Spectrometry. 21(24). 4033–4038. 102 indexed citations

17.

Murao, Naoaki, Norihisa Ohishi, Yoshiaki Nabuchi, et al.. (2004). The determination of 2β-(3-hydroxypropoxy)-1α,25-dihydroxy vitamin D3 (ED-71) in human serum by high-performance liquid chromatography–electrospray tandem mass spectrometry. Journal of Chromatography B. 823(2). 61–68. 10 indexed citations

18.

Ishigai, Masaki, et al.. (1998). Determination of 22-oxacalcitriol, a new analog of 1α,25-dihydroxyvitamin D3, in human serum by liquid chromatography–mass spectrometry. Journal of Chromatography B Biomedical Sciences and Applications. 706(2). 261–267. 17 indexed citations

19.

Ishigai, Masaki, et al.. (1998). ChemInform Abstract: Metabolism of 2(R,S)‐1,2‐Bis(nicotinamido)propane, a New Agent with Antivasospasm Activity in Rats and Rabbits.. ChemInform. 29(36). 2 indexed citations

20.

Ishigai, Masaki, et al.. (1997). Characteristics of mass spectrometric analyses coupled to gas chromatography and liquid chromatography for 22-oxacalcitriol, a vitamin D3 analog, and related compounds. Journal of Chromatography B Biomedical Sciences and Applications. 704(1-2). 11–17. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact